Icosapent ethyl reduces coronary revascularization
First and total (first and subsequent) coronary revascularization, including coronary stenting and cardiac bypass surgery, were significantly reduced by 34% and 36%, respectively with administration of 4/g day icosapent ethyl compared to placebo (both P<0.0001), shown in prespecified tertiary endpoint analyses of the REDUCE-IT trial.
These analyses from the REDUCE-IT trial included several types of coronary revascularization events in statin-treated patients with elevated triglyceride levels (135-499 mg/dL), who had CVD or diabetes with additional CV risk factors. Prespecified tertiary endpoints of urgent, emergent and elective revascularizations were reduced by 34% (P<0.0001), 38% (P=0.02), and 32% (P<0.0001), respectively, in those who received icosapent ethyl compared to placebo.
Post-hoc analyses showed that icosapent ethyl reduced percutaneous coronary intervention (PCI) by 32% (P<0.0001) and coronary artery bypass grafting (CABG) by 39% (P=0.0005) compared to placebo.
These findings were presented at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions by Benjamin Peterson, MD, Brigham and Women’s Hospital and Harvard Medical School.
REDUCE-IT was a global, CV outcomes trial that evaluated the effect of icosapent ethyl in patients on statin therapy who had elevated triglycerides between 135-499 mg/dL and established CVD or diabetes and at least one CV risk factor. 8179 Patients were enrolled at >400 clinical sites in 11 countries. Primary results were published in the NEJM in November 2018. Administration of icosapent ethyl resulted in reduction of ischemic events.
Icosapent ethyl capsules are comprised solely of the active ingredient icosapent ethyl, a unique from of eicosapentaenoic acid. It was initially approved for use as an adjunct therapy to diet to reduce triglyceride levels in adults with severe (≥500 mg/dL) hypertriglyceridemia. In December 2019, the new CV risk indication for icosapent ethyl was approved by the FDA.